WO1999003364A1 - Nutritional composition for subjects under stress - Google Patents
Nutritional composition for subjects under stress Download PDFInfo
- Publication number
- WO1999003364A1 WO1999003364A1 PCT/IB1998/001056 IB9801056W WO9903364A1 WO 1999003364 A1 WO1999003364 A1 WO 1999003364A1 IB 9801056 W IB9801056 W IB 9801056W WO 9903364 A1 WO9903364 A1 WO 9903364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- carnitine
- stress
- alkanoyl
- ginseng
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 235000016709 nutrition Nutrition 0.000 title abstract description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 14
- 240000003444 Paullinia cupana Species 0.000 claims abstract description 10
- 235000000556 Paullinia cupana Nutrition 0.000 claims abstract description 10
- -1 alkanoyl L-carnitine Chemical compound 0.000 claims abstract description 10
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 8
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000011090 malic acid Nutrition 0.000 claims abstract description 8
- 239000001630 malic acid Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims abstract description 8
- 229960000317 yohimbine Drugs 0.000 claims abstract description 8
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 7
- 244000068988 Glycine max Species 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 7
- 239000000787 lecithin Substances 0.000 claims abstract description 7
- 229940067606 lecithin Drugs 0.000 claims abstract description 7
- 235000010445 lecithin Nutrition 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000000419 plant extract Substances 0.000 claims abstract 3
- 240000004371 Panax ginseng Species 0.000 claims description 11
- 235000008434 ginseng Nutrition 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 240000000143 Turnera diffusa Species 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 235000004952 turnera diffusa Nutrition 0.000 claims description 9
- 201000001881 impotence Diseases 0.000 claims description 4
- 206010025482 malaise Diseases 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 241000682653 Corynanthe Species 0.000 claims description 2
- 235000002789 Panax ginseng Nutrition 0.000 claims description 2
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 206010003549 asthenia Diseases 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000001107 psychogenic effect Effects 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 2
- 241000190079 Turnera Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 241000675108 Citrus tangerina Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229940071325 yohimbine 5 mg Drugs 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000010242 Paullinia Nutrition 0.000 description 1
- 241001119526 Paullinia Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009206 Turnera diffusa Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress.
- This syndrome afflicts all social classes, but mainly affects people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations.
- stress syndrome is not a debilitating "disease” to the extent that it makes people bed-ridden, but it is certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown', is characterised, in the absence of active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido.
- Benzodiazepines are used to alleviate symptoms such as anxiety or irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise.
- L-carnitine when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, Lyons P, Gaf ⁇ ar MC, Sheridan MJ, Dial-Transplant, 1996, vol/iss/pg. 25/6 368-373).
- Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well known is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence”: K Reid et al., Lancet 2, 421-423 (1987). Guarana is used by Brazilian indigenous populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J Psychoactive Drugs 16 (3): 267-268, 1984).
- the purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour.
- the therapeutic medical food of the invention comprises the following compounds in combination:
- ginseng natural extract of Panax ginseng
- yohimbine natural extract of Corynanthe yohimbe
- damiana natural extract of Turnera diffusa, ⁇ ar. aphrodisiaca
- the alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
- pharmacologically acceptable salt of L- camitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects.
- acids are well known to pharmacologists and experts in pharmacy.
- Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
- the components of the combination according to the invention exhibit an unexpected potent synergistic effect which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome.
- Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido,
- the effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components.
- L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress syndrome, is aimed at enhancing the individual's general state of health.
- the weight-to-weight ratio of L-carnitine or of an alkanoyl L- carnitine to ginseng, yohimbine, guarana and damiana may vary over a broad range, This ratio should preferably range from 1:0.1:0.0025:0.1:0.1 to 1 : 10:0.25: 100:100.
- One preferred ratio is
- composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A nutritional composition (medical food) for subjects in a debilitated state as a result of stress is disclosed, which comprises a combination of: (a) L-carnitine or an alkanoyl L-carnitine or one of their pharmacologically acceptable salts; (b) a mixture of natural plant extracts (e.g. yohimbine and guarana); (c) lecithin of soya; and (d) malic acid.
Description
NUTRITIONAL COMPOSITION FOR SUBJECTS UNDER STRESS
DESCRIPTION
The present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress.
In the developed countries, stress syndrome afflicts a substantial number of people. The causes of the stress are multiple and attributable mainly to living conditions in large and overcrowded urban areas and to the problems these give rise to such as traffic, noise and pollution. Another important cause consists in problems associated with working activity or economic worries.
This syndrome afflicts all social classes, but mainly affects people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations.
Generally speaking, stress syndrome is not a debilitating "disease" to the extent that it makes people bed-ridden, but it is certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown', is characterised, in the absence of active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido.
There are no specific drugs for the treatment of stress.
Temporary detachment from the causes of the stress, for instance by spending a holiday in a pleasant locality and in a relaxing
environment, would certainly have a positive effect, facilitating recovery of mental and physical well-being with an improvement in physical performance and an increase in sexual vigour and libido. This, however, is not always possible for various reasons such as, for example, work commitments, family demands and economic difficulties.
A number of patients suffering from stress are treated with benzodiazepines or with drugs which are active in mood disorders. Benzodiazepines are used to alleviate symptoms such as anxiety or irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise.
A number of substances which are useful for the treatment of sexual impotence of psychogenic or other origin are already well known. Equally well known are substances endowed with stimulant activity. For example, L-carnitine, when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, Lyons P, Gafϊar MC, Sheridan MJ, Dial-Transplant, 1996, vol/iss/pg. 25/6 368-373).
Popular medicine (and belief) in oriental and South American countries (China, Brazil) have, since time immemorial, accredited the extracts of the roots, bark and leaves of various "exotic" plants with multiple therapeutic and stimulant effects. Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well known is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence": K Reid et al., Lancet 2, 421-423 (1987). Guarana is used by Brazilian indigenous
populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J Psychoactive Drugs 16 (3): 267-268, 1984).
The purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour. The therapeutic medical food of the invention comprises the following compounds in combination:
1) L-carnitine or an alkanoyl L-carnitine in which the linear or branched- chain alkanoyl has 2-8, and preferably 2-6, carbon atoms, or one of their pharnacologically acceptable salts;
2) ginseng (natural extract of Panax ginseng); 3) yohimbine (natural extract of Corynanthe yohimbe);
4) guarana (natural extract of Paullinia c pana);
5) damiana (natural extract of Turnera diffusa, υar. aphrodisiaca);
6) lecithin of soya, and
7) malic acid. The alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
What is meant by pharmacologically acceptable salt of L- camitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects. Such acids are well known to pharmacologists and experts in pharmacy.
Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and
acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
The components of the combination according to the invention, once combined, exhibit an unexpected potent synergistic effect which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome. Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido, The effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components.
Of particular interest is the interaction between malic acid and L-carnitine. The complementary effect exerted by these two compounds on energy production via two different metabolic pathways - malic acid via the Krebs cycle, and L-carnitine via β- oxidation - stimulates the body to produce a large amount of energy, which is useful in enabling the individual to emerge from the state of fatigue, debilitation or asthenia caused by stress.
The interaction between guarana and damiana also results in an intense stimulatory effect, enabling most subjects presenting a state of torpor or lack of interest to emerge from these conditions.
L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress syndrome, is aimed at enhancing the individual's general state of health.
The weight-to-weight ratio of L-carnitine or of an alkanoyl L- carnitine to ginseng, yohimbine, guarana and damiana may vary over a broad range, This ratio should preferably range from
1:0.1:0.0025:0.1:0.1 to 1 : 10:0.25: 100:100. One preferred ratio is
1: 1 :0.025: 1: 1.
By way of non- •limiting examples a number of sachet formulations according to the invention are given containing the following components in combination:
ComDOsition 1
L-carnitine HC1 200 mg
Ginseng 200 mg
Lecithin of soya 400 mg
Aspartame 20 mg
Sucrose 1500 mg
Tangerine flavouring 100 mg
Yohimbine 5 mg
Malic acid 50 mg
Granular mannitol q.s. to 3000 mg
Composition 2
L-carnitine HC1 200 mg
Ginseng 200 mg
Lecithin of soya 200 mg
Aspartame 20 mg
Sucrose 1000 mg
Tangerine flavouring 100 mg
Yohimbine 5 g
Guarana 200 mg
Damiana 200 mg
Malic acid 50 mg
Granular mannitol q.s. to 3000 mg
Composition 3
L-carnitine HC1 200 mg
Ginseng 200 mg
Lecithin of soya 200 mg Aspartame 20 mg
Sucrose 1000 mg
Tangerine flavouring 100 mg
Yohimbine 5 mg
Guarana 500 mg Damiana 500 mg
Malic acid 50 mg
Granular mannitol q.s. to 3000 mg
The composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors.
Claims
1. A medical food composition suitable for alleviating and treating states of malaise caused by stress, comprising the following in combination: (a) L-carnitine or an alkanoyl L-carnitine in which the linear or branched-chain alkanoyl group has 2-8, and preferably 2-6 carbon atoms, or one of their pharmacologically acceptable salts; (b) a mixture of natural plant extracts; (c) lecithin of soya;
(d) malic acid.
2. The composition of claim 1, wherein the alkanoyl L-camitine is selected from the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
3. The composition of claim 1, wherein the natural plant extracts are selected from the group comprising the natural extract of Corynanthe yohimbe or yohimbine, the natural extract of Panax ginseng or ginseng, the natural extract of Paullinia cupana or guarana, and the natural extract of Turnera difjusa or damiana.
4. The composition of claim 3, wherein the weight-to-weight ratio of L-carnitine or of an alkanoyl L-carnitine to ginseng, yohimbine, guarana and damiana ranges from 1:0.1:0.0025:0.1:0.1 to 1: 10:0.25: 100: 100.
5. The composition of claim 4, wherein said ratio is 1: 1:0.0 5; 1: 1.
6. The composition of the preceding claims, further comprising vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors.
7. The composition of any of the preceding claims for the treatment of stress-induced or psychogenic sexual impotence.
8. The composition of any of the preceding claims for the treatment of states of fatigue, lack of strength or asthenia caused by stress.
9. The composition of any of the preceding claims, which presents itself in the form of a solid, semisolid, liquid, semiliquid, powder, grains, tablets, capsules, granules, or powder for oral use.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL98338079A PL338079A1 (en) | 1997-07-16 | 1998-07-10 | Nourishing composition for persons under a stress |
| HU0004526A HUP0004526A3 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
| KR1020007000253A KR20010021694A (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
| CA002296540A CA2296540A1 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
| EP98929576A EP0999757A1 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
| JP2000502680A JP2001510026A (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for patients under stress |
| SK1819-99A SK181999A3 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
| AU79277/98A AU727448B2 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97RM000435A IT1293539B1 (en) | 1997-07-16 | 1997-07-16 | NUTRITIONAL COMPOSITION FOR SUBJECTS IN A STATE OF DEBILITATION CAUSED BY STRESS |
| ITRM97A000435 | 1997-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999003364A1 true WO1999003364A1 (en) | 1999-01-28 |
Family
ID=11405180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1998/001056 WO1999003364A1 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0999757A1 (en) |
| JP (1) | JP2001510026A (en) |
| KR (1) | KR20010021694A (en) |
| CN (1) | CN1263439A (en) |
| AU (1) | AU727448B2 (en) |
| CA (1) | CA2296540A1 (en) |
| HU (1) | HUP0004526A3 (en) |
| IT (1) | IT1293539B1 (en) |
| PL (1) | PL338079A1 (en) |
| SK (1) | SK181999A3 (en) |
| WO (1) | WO1999003364A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022263A1 (en) * | 2001-09-07 | 2003-03-20 | Ivars Kalvinsh | Pharmaceutical composition comprising gamma-butyrobetaine for stimulating the sexual activity and potency |
| AT410277B (en) * | 2001-02-22 | 2003-03-25 | Peter Dr Frigo | DRINK |
| WO2003047563A1 (en) * | 2001-12-04 | 2003-06-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
| DE102005053241A1 (en) * | 2005-11-08 | 2007-05-16 | Schwabe Willmar Gmbh & Co | Extracts of the bark of Corynanthe species and their use, as well as pharmaceuticals containing them, dietetic foods and pharmaceutical preparations |
| JP2016123324A (en) * | 2014-12-26 | 2016-07-11 | 花王株式会社 | Solid composition |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314964A (en) * | 2002-09-28 | 2005-08-02 | Boehringer Ingelheim Int | Method of increasing cognitive skills |
| US20100255127A1 (en) * | 2007-11-21 | 2010-10-07 | Kracie Pharma, Ltd. | Aromatase inhibitor |
| CN113116898A (en) * | 2021-04-20 | 2021-07-16 | 北京天玺宝科技有限公司 | Composition containing levocarnitine or acetyl levocarnitine and yohimbine with weight losing function and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| WO1997042928A1 (en) * | 1996-05-14 | 1997-11-20 | Lvmh Recherche | Topical slimming composition |
| US5744187A (en) * | 1996-12-16 | 1998-04-28 | Gaynor; Mitchel L. | Nutritional powder composition |
-
1997
- 1997-07-16 IT IT97RM000435A patent/IT1293539B1/en active IP Right Grant
-
1998
- 1998-07-10 KR KR1020007000253A patent/KR20010021694A/en not_active Withdrawn
- 1998-07-10 PL PL98338079A patent/PL338079A1/en unknown
- 1998-07-10 WO PCT/IB1998/001056 patent/WO1999003364A1/en not_active Application Discontinuation
- 1998-07-10 CA CA002296540A patent/CA2296540A1/en not_active Abandoned
- 1998-07-10 EP EP98929576A patent/EP0999757A1/en not_active Withdrawn
- 1998-07-10 HU HU0004526A patent/HUP0004526A3/en unknown
- 1998-07-10 CN CN98807193A patent/CN1263439A/en active Pending
- 1998-07-10 JP JP2000502680A patent/JP2001510026A/en active Pending
- 1998-07-10 SK SK1819-99A patent/SK181999A3/en unknown
- 1998-07-10 AU AU79277/98A patent/AU727448B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| WO1997042928A1 (en) * | 1996-05-14 | 1997-11-20 | Lvmh Recherche | Topical slimming composition |
| US5744187A (en) * | 1996-12-16 | 1998-04-28 | Gaynor; Mitchel L. | Nutritional powder composition |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410277B (en) * | 2001-02-22 | 2003-03-25 | Peter Dr Frigo | DRINK |
| WO2003022263A1 (en) * | 2001-09-07 | 2003-03-20 | Ivars Kalvinsh | Pharmaceutical composition comprising gamma-butyrobetaine for stimulating the sexual activity and potency |
| WO2003047563A1 (en) * | 2001-12-04 | 2003-06-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
| KR100907938B1 (en) * | 2001-12-04 | 2009-07-16 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | Use of alkanoyl L-carnitine for the treatment of erectile dysfunction |
| US8343979B2 (en) | 2001-12-04 | 2013-01-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of alkanoyl L-carnitine for the treatment of erectile dysfunction |
| DE102005053241A1 (en) * | 2005-11-08 | 2007-05-16 | Schwabe Willmar Gmbh & Co | Extracts of the bark of Corynanthe species and their use, as well as pharmaceuticals containing them, dietetic foods and pharmaceutical preparations |
| JP2016123324A (en) * | 2014-12-26 | 2016-07-11 | 花王株式会社 | Solid composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1263439A (en) | 2000-08-16 |
| KR20010021694A (en) | 2001-03-15 |
| AU7927798A (en) | 1999-02-10 |
| JP2001510026A (en) | 2001-07-31 |
| ITRM970435A1 (en) | 1999-01-16 |
| AU727448B2 (en) | 2000-12-14 |
| EP0999757A1 (en) | 2000-05-17 |
| SK181999A3 (en) | 2000-10-09 |
| HUP0004526A3 (en) | 2001-11-28 |
| ITRM970435A0 (en) | 1997-07-16 |
| CA2296540A1 (en) | 1999-01-28 |
| HUP0004526A2 (en) | 2001-04-28 |
| IT1293539B1 (en) | 1999-03-01 |
| PL338079A1 (en) | 2000-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6831103B1 (en) | Composition comprising theanine | |
| KR100680121B1 (en) | Preparations for the prevention and treatment of stress in warm-blooded animals containing (lyso-) phosphatidylserine | |
| US7674482B2 (en) | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods | |
| AU767492B2 (en) | Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders | |
| US5324516A (en) | Galenic composition for decreasing blood alcohol concentration | |
| JP7461066B2 (en) | Composition for enhancing sports movements | |
| JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
| KR100481188B1 (en) | Use of Alkanoyl-L-Carnitine for the Treatment of Glutamate-Related Diseases | |
| AU727448B2 (en) | Nutritional composition for subjects under stress | |
| US5482712A (en) | Galenic composition | |
| KR100711276B1 (en) | Utilization of phosphatidylserine in the treatment of attention deficit syndrome ADHS | |
| US20040213829A1 (en) | Dietary supplement | |
| JP2007500755A (en) | How to reduce symptoms of premenstrual syndrome | |
| US20030194453A1 (en) | Dietary supplement | |
| WO2002078616A2 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| AU2002305132A1 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| MXPA00000442A (en) | Nutritional composition for subjects under stress | |
| US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
| JP2008019190A (en) | Natural product-derived motivation improver | |
| KR20090024215A (en) | Means and Methods to Improve Human Sexual Activity | |
| CZ200088A3 (en) | Nutrition preparation for stress subjects | |
| EP1383579A2 (en) | Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder | |
| KR20120055159A (en) | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same | |
| KR20230106783A (en) | Composition for improving male sexual function containing mixture extract using supercritical fluid extraction method as an active ingredient | |
| WO2008152624A2 (en) | Herbal energy-enhancing formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 98807193.2 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 181999 Country of ref document: SK |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998929576 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 79277/98 Country of ref document: AU Ref document number: 501965 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09462167 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020007000253 Country of ref document: KR Ref document number: PV2000-88 Country of ref document: CZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/000442 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2296540 Country of ref document: CA Ref document number: 2296540 Country of ref document: CA Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998929576 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: PV2000-88 Country of ref document: CZ |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020007000253 Country of ref document: KR |
|
| WWG | Wipo information: grant in national office |
Ref document number: 79277/98 Country of ref document: AU |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998929576 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: PV2000-88 Country of ref document: CZ |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007000253 Country of ref document: KR |